


CERTIFICATE OF ELECTRONIC FILING

This correspondence is being filed with the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, via electronic filing, on the date below:

December 5, 2006

Date



Sharon V. Hart

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 10/620,850

Filing Date: July 15, 2003

For: Selected Antibody Compositions and
Methods for Binding to
Aminophospholipids

Group Art Unit: 1642

Examiner: Yao, L.

Atty. Dkt. No.: 4001.003082

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that the present Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. The required copies of the listed documents are enclosed, although copies of U.S. patent documents are no longer required under 37 C.F.R. § 1.98(a)(2)(ii).

In accordance with 37 C.F.R. §§ 1.97(g),(h), the present Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A first Official Action reflecting examination on the merits has been received in the present application. However, the present Information Disclosure Statement is being filed prior to the mailing of a final Official Action, notice of allowance or an action that otherwise closes prosecution, and is timely filed in accordance with 37 C.F.R. § 1.97(c)(2), with the fee set forth in 37 C.F.R. § 1.17(p).

The present Information Disclosure Statement formally makes of record the co-pending applications, although it is believed that these applications are already known to the present examiner and, indeed, the present examiner is handling certain of the listed co-pending applications. The present Information Disclosure Statement also takes the precaution of making of record the references cited in the Official Actions in the co-pending applications.

The fee set forth in 37 C.F.R. § 1.17(p) should be deducted from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/4001.003082. Should any other fees under 37 C.F.R. §§ 1.16 to 1.21 and/or any petitions be deemed necessary for any reason relating to the present materials, the present paper should be considered as the required petition and any fees deemed necessary should be deducted from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/4001.003082.

Respectfully submitted,

PEREGRINE PHARMACEUTICALS, INC.
Customer No. 000052101



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

5353 W. Alabama, Suite 306
Houston, Texas, 77056
(713) 439 0108
Date: December 5, 2006